Perspectives on the Search for a True Physiologic Replacement Therapy for Hypoparathyroidism

Abstract

Over the past two decades, we have studied various parathyroid hormone (PTH) 1-34 regimens, including once-daily and twice-daily injections without the concurrent conventional therapy. We recently studied PTH delivery by insulin pump, which produced normal, steady-state serum and urine calcium levels. The recent approval of PTH 1-84 represents an important milestone in the treatment of hypoparathyroidism. As PTH 1-84 and PTH 1-34 have similar pharmacokinetic (PK) and pharmacodynamic profiles, one can assume that many of the principles learned from studies of PTH 1-34 also apply to PTH 1-84 in the management of this rare disease.